Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qlife Holding ABOSTO:QLIFE +4.48%13 EV-to-EBITDA is -3.32 as of Aug. 07, 2026. GuruFocus rates OSTO:QLIFE with a GF Score™ of 13/100 and a GF Value™ of kr0.74 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 512 Medical Devices & Instruments companies, Qlife Holding AB ranks worse than 195312.3% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Qlife Holding AB's enterprise value is kr61.12 Mil.
Qlife Holding AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was kr-18.41 Mil. Therefore, Qlife Holding AB's EV-to-EBITDA for today is -3.32.
The historical rank and industry rank for Qlife Holding AB's EV-to-EBITDA or its related term are showing as below:
OSTO:QLIFE'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -41.23 Med: -1.61 Max: 404.96
Current: -3.33
During the past 7 years, the highest EV-to-EBITDA of Qlife Holding AB was 404.96. The lowest was -41.23. And the median was -1.61.
OSTO:QLIFE's EV-to-EBITDA is ranked worse than 100% of 512
companies
in the Medical Devices & Instruments industry
Industry Median: 14.645
vs OSTO:QLIFE: -3.33
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Qlife Holding AB (OSTO:QLIFE) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Qlife Holding AB's PE Ratio (TTM) for today is calculated as:
Qlife Holding AB's share price for today is kr1.866.
Qlife Holding AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-2.238.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Qlife Holding AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:QLIFE vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Qlife Holding AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qlife Holding AB EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Qlife Holding AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Qlife Holding AB's EV-to-EBITDA falls into.
Qlife Holding AB's current Enterprise Value is kr61.12 Mil.
Qlife Holding AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-18.41 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qlife Holding AB (OSTO:QLIFE) has a EV-to-EBITDA of -3.32 as of Aug. 07, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Qlife Holding AB. According to the industry distribution chart, Qlife Holding AB ranks #999999 out of 512 companies in the Medical Devices & Instruments industry.
Is Qlife Holding AB's EV-to-EBITDA too high?
Qlife Holding AB's current EV-to-EBITDA is -3.32. Based on the distribution chart, Qlife Holding AB ranks #999999 out of 512 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Qlife Holding AB has a GF Score™ of 13/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Qlife Holding AB's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Qlife Holding AB ranks #999999 out of 512 companies for EV-to-EBITDA. This places Qlife Holding AB in the lower half of its industry. The industry median EV-to-EBITDA is 14.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.65, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Qlife Holding AB. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qlife Holding AB's current EV-to-EBITDA is -3.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qlife Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Qlife Holding AB (OSTO:QLIFE) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.74, compared to a current price of kr1.87 — trading 152.2% above its estimated fair value. The current EV-to-EBITDA is -3.32. Qlife Holding AB's overall GF Score™ is 13/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Qlife Holding AB (OSTO:QLIFE), the current EV-to-EBITDA is -3.32 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qlife Holding AB (OSTO:QLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, Qlife Holding AB stock appears to be overvalued.
The current stock price of kr1.87 is trading 152.2% above its estimated GF Value™ of kr0.74.
GuruFocus considers Qlife Holding AB to be Significantly Overvalued.
Key valuation signals for OSTO:QLIFE:
EV-to-EBITDA: -3.32
GF Value™: kr0.74 vs. price of kr1.87 (152.2% above fair value)
No single metric tells the full story. See the OSTO:QLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qlife Holding AB is a medical device company that seeks to revolutionize the clinical biomarker testing of whole blood by taking it out of the lab and into the homes of the people who needs it. The Egoo Home System is an integrated platform consisting of a small home device and disposable capsules, each of which tests for a specific biomarker. It provides a digital infrastructure for sharing the data with the patient's doctor, clinic or hospital via smartphone and computer.
13GF Score
Get the complete analysis for OSTO:QLIFE
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:QLIFE has been successfully added to your 
